At a Glance
- Covers
- PACs; AF and pre-excited AF; atrial flutter; AVNRT and AVRT; MAT and wandering atrial pacemaker; focal atrial tachycardia; junctional rhythms
- Recognize It
- Regular narrow near 150 bpm: flutter until proven otherwise
- Irregular, no P waves: AF
- Irregular, ≥3 P shapes, isoelectric baseline: MAT
- Most Dangerous
- Pre-excited AF: irregular, very fast, wide QRS that varies in shape. AV nodal blockers can precipitate VF.
- Unstable Patient
- Synchronized cardioversion now. Pre-excited AF: electrical cardioversion. Sedate only if it will not delay the shock.
- Stable Patient
- Regular narrow: vagal maneuver, then adenosine. AF or flutter with RVR and no pre-excitation: diltiazem or verapamil (LVEF >=40%, no decompensated HF) or metoprolol. Pre-excited AF: procainamide (ibutilide only in hospital care).
- Do Not
- No AV nodal blocker (diltiazem, verapamil, adenosine, digoxin, beta-blockers, amiodarone) for a wide, irregular tachycardia that may be pre-excited AF. Polymorphic VT needs separate care. Do not cardiovert MAT (ineffective).
Physiology & What It Represents
Atrial rhythms start in the atrial myocardium or the AV junction, above the bundle of His. Each one is supraventricular, and the site of origin shapes the QRS. An impulse from the atria that travels the normal His-Purkinje system gives you a narrow QRS. Wide QRS in a supraventricular rhythm? The conduction is abnormal. Think bundle branch block, rate-related aberrancy or conduction down an accessory pathway.
Atrial arrhythmias come from three mechanisms:
- Enhanced automaticity: A focus fires faster than the sinus node. Focal atrial tachycardia and MAT are examples.
- Triggered activity: Afterdepolarizations make the cell fire early. Digoxin toxicity and electrolyte shifts are the usual triggers.
- Re-entry: A circuit keeps conducting around its loop. Atrial flutter, AVNRT and AVRT all run on re-entry. The AV node or an accessory pathway may be part of the loop.
The conduction hierarchy sets the back-up rates. Sinus node fails? The AV junction takes over at about 40–60 bpm, and the ventricles at 20–40 bpm. AV nodal blockers slow the atrial rhythms that use the AV node. The ones that skip it, like ectopic atrial tachycardia and atrial flutter, often are not slowed.
Recognition Approach
Run the same six questions on every atrial rhythm. The table lists the core rhythms with their first-line action. Stability decides that first action. The table never replaces the bedside assessment.
| Rhythm | Rate (bpm) | Regularity | P Waves | PR | QRS | First-Line Action |
|---|---|---|---|---|---|---|
| Sinus tachycardia | 100–180 | Regular | Normal, before each QRS | Normal | Narrow | Treat the cause; rate control rarely needed |
| Premature atrial complexes | Sinus rate | Regular with early beats | Early, abnormal P | Often normal | Narrow (wide if aberrant) | None usually; treat triggers |
| Atrial fibrillation | Variable (100–180 uncontrolled) | Irregularly irregular | None; fibrillatory waves | Not applicable | Narrow unless aberrant or pre-excited | Rate control if stable; synchronized cardioversion if unstable |
| Atrial flutter | ~150 at 2:1 (atrial 250–350) | Regular (fixed block) or irregular (variable) | Sawtooth flutter waves, best in II, III, aVF, V1 | Not applicable | Narrow | Rate control if stable; cardioversion if unstable |
| AVNRT | 150–250 | Very regular | Buried in QRS or pseudo-r′ V1 | Not measurable | Narrow | Vagal maneuver, then adenosine |
| AVRT (orthodromic) | 150–250 | Very regular | Retrograde P after QRS | Short RP interval | Narrow | Vagal maneuver, then adenosine |
| Pre-excited AF | Often >200 | Irregular | Fibrillatory; delta waves | Short PR | Wide, variable shape | Cardiovert if unstable; procainamide if stable (ibutilide only in hospital care) |
| Focal atrial tachycardia | 100–250 | Regular, warm-up and cool-down | Abnormal, consistent | Variable | Narrow | Rate control; ablation if refractory |
| MAT | >100 | Irregularly irregular | ≥3 P morphologies | Variable | Narrow | Treat the cause; rate control |
| Junctional rhythm | 40–60 (escape); 60–100 (accelerated) | Regular | Absent, retrograde, or buried | Short or absent | Narrow | Check digoxin and electrolytes; treat the cause |
- Find the rate: Count the R waves over 6 seconds and multiply by 10, or use the R-R interval in a regular rhythm.
- Check regularity: Regular, regularly irregular (PACs or blocks) or irregularly irregular (AF, MAT, or flutter with variable block).
- Look for P waves: Use lead II and V1. Identify sinus, ectopic, flutter, fibrillatory or absent P waves.
- Relate P to QRS: Determine the PR interval and the atrial-to-ventricular ratio. A 2:1 ratio at about 150 bpm suggests flutter.
- Measure the QRS: Narrow means supraventricular unless aberrancy is proven. Wide means assume VT or pre-excited AF until proven otherwise.
- Assess stability first: Hypotension, altered mentation, ischemic chest pain or acute heart failure means the patient is unstable and needs cardioversion.
Normal Conduction Values
| Parameter | Adult Normal | Note |
|---|---|---|
| PR interval | 120–200 ms (0.12–0.20 s; 3–5 small boxes) | Short PR <120 ms suggests pre-excitation or a junctional rhythm |
| QRS duration | ≤110 ms (≤2.75 small boxes) | ≥120 ms is wide |
| Escape rates | Junctional 40–60 bpm; ventricular 20–40 bpm | Escape rhythms are back-up rhythms for a failing sinus node |
Premature Atrial Complexes (PACs)
That early beat from an ectopic atrial focus is a premature atrial complex. You will see PACs a lot. Run a prolonged monitor on healthy adults and they turn up. They are usually benign.
ECG Criteria
- P wave: Different from the sinus P wave; the shape depends on the focus.
- Timing: Earlier than the next expected sinus P wave.
- PR interval: May be shorter, normal or longer than the sinus PR, depending on how close the focus is to the AV node.
- QRS: Usually narrow and identical to sinus beats.
- Pause: Usually incomplete, because the PAC resets the sinus node.
Aberrant PACs
Land a PAC while part of the His-Purkinje system is still refractory, and the QRS goes wide. It can pass for a PVC or VT. The right bundle branch is the most common site, so the pattern is usually RBBB-like (rsR′ in V1).
- Ashman phenomenon: A short cycle after a long one is the classic setup for aberration.
- Clue to origin: Look for an ectopic P wave buried in the preceding T wave.
Blocked PACs
Too early for the AV node? A very early PAC can arrive while the node is still refractory. Then you get a P wave with no QRS. Blocked PACs look like pauses on telemetry. Always look for a premature P wave deforming the preceding T wave.
Atrial Fibrillation (AF)
Atrial fibrillation (AF) is the most common sustained arrhythmia in clinical practice. Chaos replaces organized atrial contraction, with many re-entrant wavelets firing at once. The ventricles set their response through AV conduction. The atria have no say.
ECG Criteria
- Atrial activity: No discrete P waves. Fibrillatory waves vary in size and shape, at roughly 350–600 per minute.
- Ventricular response: Irregularly irregular R-R intervals.
- QRS: Narrow unless there is a bundle branch block, rate-related aberrancy or pre-excitation.
- Rate: Uncontrolled rates are often 100–180 bpm. AV nodal disease or drugs may slow them.
Classification
| Type | Definition | Management Implication |
|---|---|---|
| Paroxysmal | Ends on its own or with intervention within 7 days | Rhythm control often attempted; anticoagulate by stroke risk |
| Persistent | Lasts longer than 7 days | Cardioversion needs anticoagulation first or imaging |
| Long-standing persistent | Continuous for 12 months or more | Rate control is more common; ablation may be considered |
| Permanent | Rhythm control is no longer pursued | Rate control and anticoagulation are the mainstays |
The 2023 ACC/AHA/ACCP/HRS guideline adds a 1–4 staging system (with 3A–3D) that describes how the disease progresses. At the bedside, the duration terms above still apply.
Pre-Excited AF
Put AF through an accessory pathway, as in WPW, and the QRS goes wide, very fast and irregular. The shape changes from one beat to the next. Ventricular rates can exceed 200 bpm.
Clinical Significance
- Stroke risk: Anticoagulation follows CHA₂DS₂-VASc scoring. The 2023 guideline covers this for AF and typical flutter.
- Duration before cardioversion: For AF of 48 hours or more, or of unknown duration, the 2023 guideline recommends 3 weeks of uninterrupted therapeutic anticoagulation or imaging to exclude thrombus before elective cardioversion (Class 1). Anticoagulation continues for at least 4 weeks afterward (Class 1).
- Anticoagulation after emergent cardioversion: Unstable patients get emergent cardioversion, and it does not wait for anticoagulation. Start anticoagulation as soon as possible afterward.
- Pre-excited AF: AV nodal blocking agents are harmful (Class 3: Harm), since they can precipitate VF or hemodynamic collapse. Treatment is in Bedside Management.
Atrial Flutter
Atrial flutter is a macro-re-entrant circuit in the atria. The usual form, typical flutter, runs through the cavotricuspid isthmus. Unlike AF, the atrial activity is organized and repetitive.
ECG Criteria
- Flutter waves: A sawtooth pattern, best seen in II, III, aVF and V1.
- Atrial rate: 250–350 bpm, usually about 300.
- AV conduction: Usually 2:1, giving a ventricular rate of about 150 bpm. It can also be 3:1, 4:1, or variable.
- QRS: Narrow unless there is a pre-existing conduction abnormality.
- Regularity: Regular with fixed block. Irregular with variable block, which can mimic AF.
Typical vs. Atypical Flutter
- Typical, counterclockwise: The most common form. Negative sawtooth F waves in II, III and aVF, and positive in V1.
- Typical, clockwise: Less common. Positive F waves in II, III and aVF, and negative in V1.
- Atypical: Skips the cavotricuspid isthmus. Often involves the left atrium or an atrial scar. The F wave shape varies.
Clinical Significance
- Thromboembolic risk: Anticoagulation follows the same stroke-risk assessment as AF. The 2023 AF guideline covers typical flutter.
- Ablation: Ablating the cavotricuspid isthmus is a standard option for typical flutter.
AVNRT and AVRT (SVT)
Supraventricular tachycardia (SVT) is the umbrella term for paroxysmal re-entrant tachycardias. These run through the AV node or an accessory pathway. AVNRT and AVRT are the most common regular forms, and they start and stop abruptly.
AV Nodal Re-entrant Tachycardia (AVNRT)
- ECG criteria: Narrow QRS; very regular rate, usually 150–250 bpm.
- P waves: Usually buried in the QRS, or seen as a pseudo-r′ in V1 or a pseudo-S in II, III and aVF.
- Mechanism: The AV node is part of the circuit. That is why AV nodal blockers can terminate it.
AV Re-entrant Tachycardia (AVRT)
- Orthodromic AVRT: The signal goes down the AV node and comes back up the accessory pathway. The QRS stays narrow, and a retrograde P wave trails it.
- Antidromic AVRT: The signal goes down the accessory pathway and back up the AV node. The QRS is wide and passes for VT. It is rarer, and more dangerous.
- WPW pattern in sinus rhythm: Short PR (<120 ms), delta wave, and a wide QRS.
Distinguishing Features
- Abrupt onset and offset: AVNRT and AVRT start and stop like a switch. Ectopic atrial tachycardia usually warms up and cools down instead.
- Adenosine response: Stops abruptly with adenosine? Think an AV-node-dependent circuit. Slowing that unmasks flutter waves or AF points to an atrial mechanism.
Multifocal Atrial Tachycardia (MAT)
Multifocal atrial tachycardia (MAT) is an irregular supraventricular rhythm. At least three atrial foci fire independently to produce it. You see it most often with severe lung disease, and it marks acute illness.
ECG Criteria
- P wave morphology: At least three distinct P wave shapes in the same lead.
- Rate: Above 100 bpm.
- Rhythm: Irregularly irregular, which is why it is confused with AF.
- PR and PP intervals: Variable, because each focus has its own conduction time.
- Baseline: Isoelectric between P waves, unlike the fibrillatory baseline of AF.
Causes
| Category | Examples |
|---|---|
| Pulmonary | COPD (the most common setting), acute exacerbation of chronic lung disease, pneumonia |
| Cardiac | Decompensated heart failure |
| Drugs | Theophylline and aminophylline |
| Metabolic | Hypokalemia, hypomagnesemia |
| Systemic | Sepsis and critical illness |
Clinical Significance
- Cardioversion does not work: The foci are not one re-entrant circuit. There is nothing to convert. Treat the underlying cause.
- Bedside priority: MAT means acute illness is in play. Treat oxygenation, the trigger and the electrolytes.
Wandering Atrial Pacemaker
A wandering atrial pacemaker meets the same criteria as MAT: at least three P wave shapes and variable PR and PP intervals. The rate is the difference, and it stays below 100 bpm. It is usually benign. You often see it in young, healthy people or with high vagal tone.
Focal (Ectopic) Atrial Tachycardia
Focal atrial tachycardia comes from one atrial focus, driven by enhanced automaticity or triggered activity. Unlike MAT, the P wave keeps the same shape on every beat.
ECG Criteria
- Rate: Usually 100–250 bpm.
- P wave: Abnormal shape, the same on each beat, and different from sinus.
- Onset and offset: Gradual warm-up and cool-down, unlike the abrupt start and stop of AVNRT and AVRT.
- AV conduction: Variable. Some beats may be blocked, which can produce a pattern like 2:1 AV block.
Causes
- Digoxin toxicity, which drives triggered activity. Check the level and the potassium.
- Electrolyte shifts that change atrial automaticity.
Look-Alikes
- MAT: Irregular, with three or more P wave shapes. See Multifocal Atrial Tachycardia (MAT).
- AVNRT and AVRT: Abrupt onset and offset with a fixed relationship. See AVNRT and AVRT (SVT).
Adenosine may transiently slow focal atrial tachycardia or unmask its P waves. It often fails to terminate it. It can terminate some focal ATs, especially those from triggered activity. Termination therefore does not fully exclude an atrial source. Management is in Bedside Management.
Junctional Rhythms
Junctional rhythms start in the AV junction: the AV node or the bundle of His. They are supraventricular. They get their own category because the P wave timing is different.
ECG Criteria
| Rhythm | Rate | Key Feature |
|---|---|---|
| Junctional escape | 40–60 bpm | Back-up rhythm when the sinus rate falls below the junctional rate |
| Accelerated junctional | 60–100 bpm | Often benign; seen with digoxin, after cardiac surgery, or with inferior MI |
| Junctional tachycardia | >100 bpm | Consider digoxin toxicity, myocarditis or post-surgical states |
- P waves: Absent, retrograde (inverted in II, III, aVF), or buried in the QRS.
- QRS: Narrow unless there is a pre-existing bundle branch block.
Clinical Significance
A junctional rhythm can signal a failing sinus node or digoxin toxicity. When it shows up without a clear cause, check the digoxin level and the potassium. Bedside management is in the section below.
Differential Diagnosis & Mimics
Irregularly irregular and fast rhythms cause the most errors. The table sets the three most-confused rhythms side by side.
| Feature | Atrial Fibrillation | MAT | Flutter with Variable Block |
|---|---|---|---|
| Baseline | Fibrillatory, chaotic | Isoelectric between P waves | Sawtooth flutter waves |
| P waves | None discrete | At least 3 shapes | Single flutter-wave shape |
| Rhythm | Irregularly irregular | Irregularly irregular | Irregular, with a set pattern of blocks |
| Rate | Often 100–180 | Above 100 | About 150 at 2:1; faster with less block |
| Response to cardioversion | Can convert | Does not convert | Converts with cardioversion or ablation |
Artifact & Lead Misplacement
- Shivering or tremor: Looks like AF or flutter. Look for a constant baseline alongside the QRS.
- Limb lead reversal: Can make P waves look inverted. Check that the pattern matches sinus rhythm in lead II.
- Transport vibration: Moving the monitor or the patient can fake a fibrillation-like baseline. Reassess once the vehicle stops.
- Electrode problems: A loose electrode gives you a wandering baseline. Reposition the lead before you treat.
Normal Variants
Sinus arrhythmia and PACs can make the rhythm look irregular with no true arrhythmia. Check the P wave before the QRS on each beat.
Bedside Management & Escalation
Start with stability. An unstable patient with a tachycardia needs synchronized cardioversion, not drugs. Stable patients can get drugs in the order below. Those doses track the 2025 AHA Guidelines, and the table marks where the FDA label disagrees.
Stability Approach
| Situation | BLS (EMT) | ALS (AEMT / Paramedic / RN) | Critical Care / Transport |
|---|---|---|---|
| Unstable tachycardia | Oxygen if SpO₂ <94%; monitor the rhythm and pulse; call ALS and do not delay transport. Pads and CPR only if pulseless. | Synchronized cardioversion now, sedate only if it will not delay the shock. Transmit a 12-lead ECG if permitted. | Synchronized cardioversion; pads anterior-posterior; continuous monitoring; notify the receiving team (Paramedic/RN/CCT). |
| Stable, narrow, regular (SVT or flutter) | Notify ALS; help with vagal maneuver if trained. | Modified Valsalva; then adenosine. If it fails, a non-dihydropyridine CCB or metoprolol (no pre-excitation, no HFrEF). | Same drug choices; repeat ECG; watch for BP drop after diltiazem or verapamil. |
| Stable, regular, wide (treat as VT) | Notify ALS. Do not give AV nodal blockers. | Treat as VT: expert consultation; amiodarone, procainamide or sotalol may be considered (2025 AHA Part 9, COR 2b). Synchronized cardioversion if unstable (100 J; COR 1). Adenosine may be considered only if hemodynamically stable, regular and monomorphic (2025 AHA Part 9, COR 2b); never if hemodynamically unstable, irregularly irregular or polymorphic (COR 3: Harm, C-LD). No verapamil or diltiazem (COR 3: Harm). See Ventricular Rhythms. | Defibrillator at bedside; expert consultation; avoid AV nodal blockers. |
| Stable, irregular, wide (suspected pre-excited AF) | Notify ALS. Do not give drugs. | Procainamide (stable). Ibutilide only in hospital or critical care (boxed torsades warning). Cardiovert if unstable or if drugs fail. | Defibrillator at bedside; avoid AV nodal blockers; expert consultation. |
Rate Control in AF
- Target: Lenient is fine: a resting rate under 100 to 110 bpm is reasonable (2023 guideline, Class 2a). Relieve symptoms and check hemodynamics first.
- LVEF 40% or more, no decompensated HF, not hypotensive: diltiazem or verapamil (Therapy Table), or metoprolol.
- LVEF below 40% or decompensated HF: Avoid diltiazem and verapamil (2023 guideline: Class 3, Harm, for moderate or severe LV systolic dysfunction, and 2025 AHA Part 9: Class 3, Harm, C-EO, in decompensated HF or LV systolic dysfunction). Your options are IV amiodarone, which is Class 2a (B-NR) for rate control in critically ill adults without pre-excitation (2025 AHA Part 9), plus digoxin as an adjunct. Bring in expert or critical-care input.
- Unstable AF: Cardiovert now. Do not wait for anticoagulation (2025 AHA Part 9, COR 1, LOE C-LD). Start it as soon as possible afterward.
Therapy Table
| Therapy | Adult | Pediatric | Key Notes |
|---|---|---|---|
| Modified Valsalva | Strain 15 s against about 40 mm Hg, then lie back with passive leg raise | Age-appropriate technique; per PALS | Standard Valsalva ends 20–30% of narrow-complex tachycardias; modified techniques reach up to 50% (2025 AHA Part 9). In the REVERT RCT, a modified technique converted 43% vs 17% with standard Valsalva. Use before adenosine when stable. Avoid carotid sinus massage in older adults or with carotid bruits. |
| Adenosine (adenosine) | 6 mg rapid IV/IO push, then rapid saline flush; 12 mg if no response in 1–2 min. Max 12 mg per dose. Central line or post-heart transplant: 1 mg may be adequate (2025 AHA Part 9). Dipyridamole: smaller doses may be effective (label; no number given). Carbamazepine: can increase heart block (label). | 0.1 mg/kg rapid IV/IO (max 6 mg), then 0.2 mg/kg (max 12 mg) | Contraindicated in 2nd- or 3rd-degree AV block or sick sinus syndrome without a pacemaker. Contraindicated in asthma or active bronchospasm: it can cause severe bronchospasm (2025 AHA Part 9). Not for irregular or polymorphic wide-QRS tachycardia. Methylxanthines (caffeine, theophylline) blunt the effect. Defibrillator ready. |
| Diltiazem (diltiazem) | 0.25 mg/kg IV over 2 min (about 20 mg); at 15 min if needed 0.35 mg/kg over 2 min. Infusion 5–10 mg/hr (2025 AHA Part 9, Table 2). Differs from FDA label: the label allows titration up to 15 mg/hr. | Not established in children; specialist use only | Avoid if LVEF <40%, decompensated HF or hypotension. Never in pre-excited AF or wide-complex tachycardia. Not after an IV beta-blocker. |
| Verapamil (verapamil) | 0.075–0.15 mg/kg IV over 2 min (about 5–10 mg at 70 kg; 2025 AHA Part 9, Table 2); an additional dose after 30 min if no response. Older adults: over at least 3 min. | Age 1–15 years, specialist use: 0.1–0.3 mg/kg IV over ≥2 min (max 5 mg). Infants: not routinely used | Some protocols start at 2.5–5 mg. Avoid with hypotension, HFrEF, sick sinus syndrome, AV block or recent IV beta-blocker. Never in wide-complex tachycardia or pre-excited AF. |
| Metoprolol (metoprolol) | 2.5–5 mg IV over 2 min, up to 3 doses (max 15 mg) | Not established for IV use in children | High-alert Avoid in decompensated heart failure. No IV CCB within a few hours. |
| Amiodarone (amiodarone) | AF or flutter rate control when other agents fail or are unsuitable: 300 mg IV over 1 h, then 10–50 mg/h over 24 h (2025 AHA Part 9, Table 2; multiple schemes exist). Differs from FDA label: IV amiodarone is labeled for ventricular arrhythmias, not AF rate control. VT (stable, wide QRS): 150 mg IV over 10 min, then 1 mg/min for 6 hours (2025 AHA ACLS tachyarrhythmia algorithm) | Not established in children; specialist use only. Refractory SVT with cardiopulmonary compromise when expert consultation is unavailable: procainamide, amiodarone or sotalol may be considered (2025 AHA Part 8, SVT rec 5, COR 2b). | High-alert Contraindicated in pre-excited AF (Class 3: Harm). Pediatric arrest dose (VF or pVT) is a separate 5 mg/kg bolus (max 300 mg), repeatable up to 3 doses (2025 AHA PALS cardiac arrest algorithm); not for perfusing SVT. |
| Procainamide (procainamide) | Stable pre-excited AF or stable wide-complex tachycardia: 20–50 mg/min IV until arrhythmia suppressed, hypotension, QRS widens over 50%, or 17 mg/kg maximum (2025 AHA ACLS algorithm). Differs from FDA label: the label caps the load at 1 g; 17 mg/kg is about 1.2 g at 70 kg. | 15 mg/kg IV/IO over 30–60 min (PALS 2020 algorithm dose; the 2025 PALS algorithm lists no procainamide dose); specialist (pediatric cardiology) use; expert consultation | High-alert Boxed warning: positive ANA, blood dyscrasias, and excess mortality in structural heart disease or after MI (CAST). Avoid in heart failure, prolonged QT, complete heart block and lupus. Harmful in torsades or polymorphic VT: confirm pre-excited AF (delta wave or prior WPW; rate; QRS varying in shape) before use, or get expert advice. |
| Ibutilide | Stable pre-excited AF, hospital or critical care only: 1 mg IV over 10 min if 60 kg or more, or 0.01 mg/kg if under 60 kg; one repeat 10-min infusion if still in rhythm 10 min after the first | Not established; specialist use only | High-alert Boxed warning: potentially fatal polymorphic VT or torsades. Correct potassium and magnesium first; avoid with QT prolongation or low EF or heart failure. Continuous ECG for at least 4 hours after infusion. Not standard EMS. |
| Magnesium sulfate (magnesium sulfate) | Empiric add-on for MAT or rate control that lags: 2 g IV over about 15 min | Correct a deficit: 25–50 mg/kg IV/IO (max 2 g) | High-alert IV magnesium is a 2023 AF guideline Class 2a add-on for rate control. Check renal function. |
| Synchronized cardioversion (cardioversion) | AF: at least 200 J biphasic first shock, escalated if it fails (2025 AHA Part 9, COR 2a); atrial flutter 200 J (COR 2b); narrow-complex tachycardia 100 J; monomorphic VT 100 J (2025 AHA ACLS cardioversion algorithm). | 0.5–1 J/kg, then 2 J/kg if no response (2025 AHA Part 8, COR 2a) | Turn SYNC on and confirm a marker on each R wave. Sedate only if it will not delay an unstable shock. |
Your scope of practice and local protocol decide which of these drugs you may give.
Pediatric & Special Populations
Pediatrics
- Heart rate: Normal sinus rates fall as kids get older. Compare them with the age-based values on pediatric vital signs.
- SVT rates: Infant SVT is usually above 220 bpm, and child SVT usually above 180 bpm. Pediatric SVT with a pulse and poor perfusion gets synchronized cardioversion, per PALS. Adenosine may go first, but only if IV or IO access is already in place and it will not delay cardioversion.
- Drug choices: Adenosine is the first-line drug for stable SVT. Verapamil is not routinely used in infants. Diltiazem and metoprolol are not established in children.
- Weight-based dosing: Use the weight-based dosing reference. Respect the maximum for every drug.
Other Populations
- Pregnancy: Vagal maneuvers, then adenosine, come first for regular SVT. Electrical cardioversion is used when needed at any gestational age, with fetal monitoring. Use left lateral tilt after about 20 weeks. Avoid amiodarone when alternatives exist. For AF with manifest pre-excitation, IV procainamide is an option (2023 AF guideline). Involve OB or MFM.
- Older adults: Give verapamil over at least 3 minutes. Plan on lower doses, and expect more bradycardia and hypotension.
- Heart transplant: The denervated heart responds poorly to atropine. Adenosine can cause prolonged asystole. Use the reduced dose and get expert input.
- Pacemaker or ICD: Check the device before you cardiovert. Device therapies may already have treated the rhythm.
Monitoring & Transport Considerations
| Issue | What to Do |
|---|---|
| Best lead for P waves | Lead II. Use V1 when flutter waves are the question. |
| Wide-complex tachycardia | Use V1 or MCL1 to judge morphology, and confirm the rhythm before choosing drugs. |
| Artifact | Shivering, vibration and movement can mimic AF or flutter. Stop the vehicle or pause motion before judging the rhythm. |
| Pads | Place anterior-posterior pads before moving an unstable tachycardia or bradycardia patient. |
| Infusions | Set alarm limits and confirm pump rates for diltiazem, verapamil and procainamide. Diltiazem bolus is mg/kg and the infusion is mg/hr; never mix the two. |
| After conversion | Repeat the rhythm strip and a 12-lead ECG. Watch for recurrence and post-shock hypotension. |
| Transmission | Send a 12-lead ECG where local protocol allows, and note the time of each drug and each shock. |
Step-by-Step Approach & Pitfalls
- Check the patient first: Note blood pressure, mental status, chest pain and heart failure signs. Unstable means cardiovert.
- Measure the QRS in the widest lead: Narrow or wide determines the drug pathway.
- Check regularity: Regular or irregularly irregular.
- Find the P waves: Use lead II and V1. Classify them as sinus, ectopic, flutter, fibrillatory or absent.
- Relate P to QRS: Note the PR and the atrial-to-ventricular ratio.
- Choose the pathway: Narrow regular goes to vagal then adenosine. Irregular wide goes to procainamide or cardioversion. Regular wide is VT until proven otherwise: see Ventricular Rhythms. Irregular narrow with a rate problem goes to rate control.
- Reassess after each step: Rate, BP and rhythm after every drug or shock.
Common Pitfalls
- Calling a wide, irregular rhythm AF. Check for pre-excitation first.
- Cardioverting MAT. It will not convert.
- Giving diltiazem or verapamil for an unidentified wide-complex tachycardia. Identify it first.
- Mistaking blocked PACs or flutter with variable block for a true pause or AF.
- Forgetting the anticoagulation requirement before elective cardioversion of AF of 48 hours or more.
Clinical Pearls
References
- Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. Circulation. 2024;149(1):e1–e156. https://doi.org/10.1161/CIR.0000000000001193
- American Heart Association. Part 9: Adult Advanced Life Support: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2025;152(16 suppl 2):S538–S577. https://doi.org/10.1161/CIR.0000000000001376
- American Heart Association. Part 1: Executive Summary: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2025;152(16 suppl 2):S284–S312. https://doi.org/10.1161/CIR.0000000000001372
- Brugada J, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardia. Eur Heart J. 2020;41(5):655–720. https://doi.org/10.1093/eurheartj/ehz467
- American Heart Association and American Academy of Pediatrics. Part 8: Pediatric Advanced Life Support: 2025 American Heart Association and American Academy of Pediatrics Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. https://cpr.heart.org/en/resuscitation-science/cpr-and-ecc-guidelines/pediatric-advanced-life-support
- Appelboam A, et al. Postural modification to the standard Valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): a randomised controlled trial. Lancet. 2015;386(10005):1747–1753. https://doi.org/10.1016/S0140-6736(15)61485-4
Medical Disclaimer
- For Educational Purposes Only: This content is intended for educational reference and should not be used for clinical decision-making.
- Not a Substitute for Professional Judgment: Always consult your local protocols, institutional guidelines, and supervising physicians.
- Verify Before Acting: Users are responsible for verifying information through authoritative sources before any clinical application.